Skip to main content
OpenTrials
Completed

NCT Number: NCT04060654

SUBLOCADE Rapid Initiation Extension Study

A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study is being conducted to assess the longer-term safety of an abbreviated initiation protocol of SUBLOCADE in subjects who have completed the INDV-6000-403 study. It is also to provide treatment to these individuals while they seek longer-term treatment arrangements, as on average it can take an individual with opioid use disorder (OUD) 6 months between seeking treatment and achieving an appointment at a provider in the United States (US).

Subjects who have completed the end of treatment (EOT) procedures for the INDV-6000-403 study may be eligible for participation. It is planned that the EOT visit for INDV-6000-403, which will occur approximately 28 days after the subject's first dose of SUBLOCADE, and Day 1 for INDV-6000-404 will occur within 2 days of the EOT visit, and that EOT assessments will serve as the screening assessments for this study.

On Day 1, eligible subjects will receive a subcutaneous (SC) injection of 300 mg SUBLOCADE. Subjects will return to the clinic for subsequent injections approximately every 4 weeks for a total of up to 5 injections. Adverse events and concomitant medications will be captured throughout the study, female subjects of childbearing potential will receive urine pregnancy tests and all subjects will have urine drug screening (UDS) and evaluation of the previous injection site performed. Subjects will otherwise be treated in accordance with local standard of care, and SUBLOCADE doses will be based on the medical judgment of the Investigator.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed the informed consent form (ICF) and have the ability to comply with the requirements and restrictions listed therein.
  • Completed the EOT Visit for the INDV-6000-403 Study.
  • Is an appropriate candidate in the opinion of the Investigator or medically qualified sub-Investigator.

Exclusion criteria

  • Subject compliance issues during participation in the INDV-6000-403 study which, in the opinion of the Investigator, could potentially compromise subject safety.
  • Subjects who are unable, in the opinion of the Investigator or Indivior, to comply fully with the study requirements including those who are currently incarcerated or pending incarceration legal action.

Treatment and study plan

SUBLOCADE

Drug

SUBLOCADE to be administered approximately every 4 weeks per local standard of care

Other names: Extended release buprenorphine

Primary outcomes

  1. Treatment Emergent Adverse Event (TEAE) Occurrence

    Time frame: From time of informed consent at Day 1 until EOT, assessed up until Day 141

    Study will report the number of participants with the occurrence of any TEAE during the treatment period.

Sponsors and collaborators

Lead sponsor

Indivior Inc.

Industry

Registry information

Official study title

An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE™)

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Aug 19, 2019
Registry last updated
Mar 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.